Optimi Health is trading 7.06% higher at $5.31 after completing and quality-releasing a 5mg psilocybin capsule batch on September 23, 2026.
- The batch will support a Health Canada-approved Phase 2 major depressive disorder trial.
- It will also support commercial treatment-resistant-depression supply for Australian clinics. Broader markets were weaker, making the company-specific announcement the clearest catalyst.